Baker McKenzie advised Xbrane Biopharma on the deal.Xbrane Biopharma AB (publ) executed a primary issuance of shares of approximately SEK 170 million at a subscription price of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
